ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019
Rapid and Extensive Expansion in the United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence Type 1193.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.Clinical microbiology reviews · 2019Pooled it
- Clinical Characteristics, Antibiotic Resistance Trends, and Associated Molecular Epidemiology Traits inOpen forum infectious diseases · 2026Article
- Molecular Epidemiology and Multilevel Drug Resistance Mechanisms ofInfection and drug resistance · 2026Review
- Article
- Comparative genomic and phenotypic analysis of Escherichia coli ST1193 and ST131 from urinary and bloodstream infections: insights into resistance, virulence, and divergent strategies.BMC infectious diseases · 2025Article
- De Novo Design of Miniprotein Inhibitors of Bacterial Adhesins.Research square · 2025Article
- Trends in UropathogenicOpen forum infectious diseases · 2025Article
- Tracing the evolutionary dynamics of carbapenem-resistant Escherichia coli in recurrent and multi-site infections.Gut pathogens · 2025Article
- Article
- Phenotypic and Genotypic Characterization of ESBL-, AmpC-, and Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Pathogenesis and Immunomodulation of Urinary Tract Infections Caused by UropathogenicMicroorganisms · 2025Review
- Wastewater based genomic surveillance key to population level monitoring of AmpC/ESBL producing Escherichia coli.Scientific reports · 2025Article
- Comparative analysis of virulence-associated genes in ESBL-producingFrontiers in microbiology · 2025Article
- Predicting sepsis mortality into an era of pandrug-resistant E. coli through modeling.Communications medicine · 2024Article
- High-riskeLife · 2024Article
- Gut residentmedRxiv : the preprint server for health sciences · 2024Article
- Multidrug resistance plasmids commonly reprogram the expression of metabolic genes inmSystems · 2024Article
- A convergent evolutionary pathway attenuating cellulose production drives enhanced virulence of some bacteria.Nature communications · 2024Article
- The complete genome sequence of five pre-2013 Escherichia coli sequence type (ST)1193 strains reveals insights into an emerging pathogen.Access microbiology · 2024Article
- Fluoroquinolone resistance in complicated urinary tract infections: association with the increased occurrence and diversity ofFrontiers in cellular and infection microbiology · 2024Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
We describe the rapid and ongoing emergence across multiple US cities of a new multidrug-resistant Escherichia coli clone-sequence type (ST) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (53%). ST1193 is associated with younger adults (age <40 years) and currently comprises a quarter of fluoroquinolone-resistant clinical E. coli urine isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.